Lumenis announced the support of a medical symposium entitled “Controversy in Treatment of Airway Papillomas”, be held on Friday, April 29, 2011, at the annual COSM, in Chicago. Santa Clara, CA (PRWEB) April 25, 2011 Lumenis Ltd., the world’s largest medical laser company, announced the support of a medical symposium entitled, “Controversy in Treatment of Airway Papillomas,”to be held on Friday, April 29, 2011, at the annual COSM, in Chicago.

Researchers found people with lung cancer were significantly more likely to have several high-risk forms of human papillomavirus (HPV) antibodies compared to those who didn’t have lung cancer.

Researchers with the International Agency for Research on Cancer (IARC) have found that people with lung cancer were significantly more likely to have several high-risk forms of human papillomavirus (HPV) antibodies compared to those who did not have lung cancer.

CAMBRIDGE, Mass., June 7 /PRNewswire/ -- OmniGuide (http://www.omni-guide.com/) announced today that the initial patients have been treated in a clinical study evaluating patient quality of life and airway patency.

Abstract Objective: Determination of early prognostic factors in patients with recurrent respiratory papillomatosis is extremely important, so the major goal of our prospective, multicentre study was to evaluate (1) the feasibility of various factors to determine prognosis of the clinical course, as well as (2) the response to interferon-alpha therapy in recurrent respiratory papillomatosis.